RPGLIFE.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 12:59):

Stats
Объем за сегодня	11 523.00
Средний объем	19 949.00
Рыночная капитализация	23.97B
EPS	INR8.01 ( 2024-05-02 )
Дата следующего отчета о доходах	( INR0 ) 2024-07-25
Last Dividend	INR12.00 ( 2023-07-21 )
Next Dividend	INR0 ( N/A )
P/E	28.30
ATR14	INR2.30 (0.16%)

Объем Корреляция

Длинно: 0.01 (neutral)

Кратко: -0.99 (very strong negative)

Signal:(42.93) Neutral

RPG Life Sciences Limited Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

RPG Life Sciences Limited Корреляция - Валюта/Сырье

0.78
( moderate )

0.70
( moderate )

0.79
( moderate )

0.78
( moderate )

0.59
( weak )

-0.66
( moderate negative )

RPG Life Sciences Limited Финансовые показатели

Annual	2023
Выручка:	INR5.82B
Валовая прибыль:	INR2.48B (42.66 %)
EPS:	INR53.01

FY	2023
Выручка:	INR5.82B
Валовая прибыль:	INR2.48B (42.66 %)
EPS:	INR53.01

FY	2022
Выручка:	INR5.13B
Валовая прибыль:	INR3.42B (66.68 %)
EPS:	INR40.90

FY	2022
Выручка:	INR4.37B
Валовая прибыль:	INR2.87B (65.64 %)
EPS:	INR31.13

Financial Reports:

No articles found.

RPG Life Sciences Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR9.60 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR12.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

RPG Life Sciences Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.98 - good (79.75%) | Divividend Growth Potential Score: 5.56 - Stable (11.27%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.200	2008-08-11
Last Dividend	INR12.00	2023-07-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR51.04	--
Avg. Dividend % Per Year	1.03%	--
Score	3.1	--
Div. Sustainability Score	7.98
Div.Growth Potential Score	5.56
Div. Directional Score	6.77	--

Next Divdend (Est)
(2024-06-27)

INR13.68 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.10

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.40	0.61%
2019	INR2.40	1.01%
2020	INR4.00	1.26%
2021	INR7.20	1.92%
2022	INR9.60	1.57%
2023	INR12.00	1.41%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SOUTHBANK.NS	Dividend Junior	2023-08-17	Sporadic	25	0.42%
MONARCH.NS	Dividend Junior	2023-09-14	Annually	3	0.20%
HERANBA.NS	Dividend Junior	2023-08-17	Annually	4	0.20%
BHEL.NS	Dividend Junior	2023-08-11	Annually	21	0.26%
RAMCOIND.NS	Dividend Junior	2023-08-02	Annually	23	0.32%
KOKUYOCMLN.NS	Dividend Junior	2023-07-20	Sporadic	16	0.16%
EQUITASBNK.NS	Dividend Junior	2023-07-27	Insufficient data to determine frequency	2	0.56%
ALKEM.NS	Dividend Junior	2023-08-09	Semi-Annually	9	0.71%
SWARAJENG.NS	Dividend Knight	2023-07-06	Annually	23	2.81%
NELCO.NS	Dividend Junior	2023-06-06	Sporadic	22	0.24%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.151	1.500	6.99	10.00	[0 - 0.5]
returnOnAssetsTTM	0.171	1.200	4.30	5.16	[0 - 0.3]
returnOnEquityTTM	0.259	1.500	8.23	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.28	0.800	3.62	2.90	[1 - 3]
quickRatioTTM	1.342	0.800	6.81	5.45	[0.8 - 2.5]
cashRatioTTM	0.278	1.500	9.56	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	370.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	15.22	2.00	4.93	9.85	[0 - 30]
freeCashFlowPerShareTTM	15.22	2.00	2.39	4.78	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.557	1.000	4.06	4.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.197	1.000	8.05	8.05	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	1.135	0.800	5.77	4.61	[0.5 - 2]
Total Score				7.98

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	27.25	1.000	7.35	0	[1 - 100]
returnOnEquityTTM	0.259	2.50	8.86	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	15.22	2.00	4.93	4.78	[0 - 30]
dividendYielPercentageTTM	0.830	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.22	2.00	4.93	9.85	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.950	1.500	7.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0432	1.000	-1.419	0	[0.1 - 0.5]
Total Score				5.56

RPG Life Sciences Limited

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.